24/7 Market News Snapshot 07 August, 2025 – OS Therapies Incorporated (NYSE:OSTX)

August 7, 2025

DENVER, Colo., 07 August, 2025 (www.247marketnews.com) – (NYSE:OSTX) are discussed in this article.
OS Therapies Incorporated (OSTX) is currently witnessing a bullish trajectory in its stock performance, trading at $1.941 during pre-market hours, marking a notable increase of 10.91% from the previous close of $1.750. This positive shift is bolstered by a robust trading volume of 1.12 million shares, indicative of substantial investor engagement. Market analysts suggest that the recent momentum reflects heightened optimism regarding the company’s future prospects. It is critical for stakeholders to observe key support levels around $1.750 while remaining vigilant for potential resistance near the psychologically significant barrier of $2.00. Sustained buying interest may solidify the company’s optimistic outlook.

In parallel, OS Therapies has made significant strides in its regulatory journey concerning its lead asset, OST-HER2, which is being developed for the prevention or delay of recurrent pulmonary metastatic osteosarcoma in patients with a history of the disease. Following a successful Scientific Advice Meeting with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in July, the company proceeded to submit an application for the Innovative Licensing and Access Pathway (ILAP). This strategic move positions OS Therapies advantageously for rapid regulatory approval. Furthermore, the MHRA encouraged the company to pursue Project Orbis—an initiative designed to expedite the approval process across international regulatory bodies for simultaneous submissions.

Paul Romness, MPH, CEO of OS Therapies, expressed satisfaction with the meeting’s results, reiterating the company’s commitment to collaborating with both the FDA and MHRA to facilitate OST-HER2’s approval for osteosarcoma patients. With promising outcomes recorded in Phase 2b clinical trials—highlighting statistically significant improvements in 12-month event-free survival—OST-HER2 is gaining recognition in pediatric oncology. The company is also engaging with the European Medicines Agency to initiate the Marketing Authorisation Application process, further affirming its commitment to bringing innovative treatments to market. As OS Therapies continues to advance its initiatives, it will keep stakeholders informed regarding developments surrounding OST-HER2 and other groundbreaking therapies.

Related news for (OSTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.